This year again, following success of previous four years, we are delighted to announce our 5th Annual Cancer BioPartnering & Investment Forum to take place on the 28th of March at the New York Academy of Sciences. Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding/investment.
Dr. Glynn Wilson, Chairman and CEO of TapImmune, will provide an overview of the company’s business, clinical pipeline and partnering opportunities for its proprietary PolyStart technology platform during his presentation at the 5th Annual Cancer Biopartnering & Investment Forum hosted by Sachs Associates in New York, NY. Additionally, Dr. Wilson will serve as a panelist during the conference’s “Cancer Vaccines: Immuno-Priming and Tumor Antigens” panel discussion.
|Sachs’ 5th Annual Cancer Biopartnering & Investment Forum|
|Date:||Tuesday, March 28, 2017|
|Times:||Company presentation: 10:35 am (Eastern Time)
Cancer vaccine panel discussion: 2:00 pm (Eastern Time)
|Location:||The New York Academy of Sciences, New York, NY|
Watch the company presentation live below.